NEW YORK (Reuters Health)—The investigational drug abaloparatide may help postmenopausal women increase their bone mineral density (BMD) and reduce their risk of fracture, new industry research suggests. “What was surprising and very important about this study was that, although some drugs for osteoporosis don’t work across all patient subgroups, abaloparatide provided persistent protection against fracture…
Innate Immune Response Enters Center Stage for Inflammatory Eye Disease
Researchers suspect the C-type lectin receptor (CLR) mincle may play a role in experimental autoimmune uveoretinitis. A new study linked CLR mincle to Card9-signaling events and IL-1, resulting in inflammation…
From the Expert: New Advances in Treatment of Systemic Scleroderma
A recent study found that mycophenolate mofetil is an effective alternative for the treatment of systemic scleroderma with interstitial lung disease, resulting in possible long-term improvement. According to Aryeh Fischer, MD, this new research points to the future expansion of treatment options…
OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients
Clinical trials have begun to determine if disodium zoledronate tetrahydrate is safe and effective for treating pain in patients with knee osteoarthritis. The FDA has approved the use of ixekizumab for the treatment of plaque psoriasis. And a study has shown that patients with SLE treated with belimumab may be able to decrease steroid use…
CMS Commences 45-Day Open Payments Review & Dispute Period
On April 1, the Centers for Medicare and Medicaid Services (CMS) announced the beginning of the 45-day Open Payments Review and dispute period, which will conclude on May 15. After the review period concludes, on June 30, CMS will publish 2015 payment data along with updates to the 2013 and 2014 data. If you are…
Platelet-Rich Plasma Therapy May Treat Degenerative Tendinopathies & Pain
A recent small-scale study showed that patients who received platelet-rich plasma therapy for tendon healing experienced clinically important improvements in pain and disability compared with placebo. Additionally, MRI showed that some participants had improvement in the pathoanatomy of the rotator cuff six months after treatment…
2015 ACR/ARHP Annual Meeting: Global Challenges in Rheumatic Disease Care
SAN FRANCISCO—To convey the plight of rheumatology patients in sub-Saharan Africa, Girish Mody, MD, head of rheumatology at the University of KwaZulu-Natal in South Africa and past president of the African League of Associations for Rheumatology, recounted a story during the 2015 ACR/ARHP Annual Meeting from the World Health Organization about a diabetes patient. The…
Sifalimumab Shows Some Promise Against Lupus
NEW YORK (Reuters Health)—Sifalimumab, an anti-interferon alpha monoclonal antibody, may lead to some improvement in patients with systemic lupus erythematosus (SLE), according to a new trial. In a paper online on March 23 in Annals of the Rheumatic Diseases, Dr. Munther Khamashta of King’s College London and colleagues note that treatment of SLE presents a…
The Microbiome in Pediatric Rheumatic Diseases
The human intestinal microbiota is home to more than 1,000 bacterial species, containing approximately 3 million genes, many of which code for functions that have the potential to affect human physiology.1 Smaller numbers of organisms are also present in the skin, upper gastrointestinal tract, female reproductive tract and the oro- and nasopharynx. As tools have…
Technological Advances Linked to Medical Misadventures
For keen students of American politics, the unending intrigue of the 2016 presidential race has been riveting. With an assemblage of aspiring candidates that, at its start, included a bevy of U.S. senators and former governors, a media-savvy real estate mogul, a renowned Hopkins neurosurgeon and an ophthalmologist, political junkies among us have feasted on…
- « Previous Page
- 1
- …
- 488
- 489
- 490
- 491
- 492
- …
- 796
- Next Page »